BiME® Franchise
Building on the BiME® platform, we are advancing several programs to fully leverage its innovative potential. Our BiME pipeline targets tumors with a high abundance of tumor-associated macrophages (TAMs), including HCC, GC, and CRC, where effective therapies remain limited.
The novel bispecific antibody macrophage engagers generated from this platform have the potential to transform clinical practice by reactivating macrophages and enhancing anti-tumor immunity in challenging cancer types.